Trial
NCT01605162
Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Eisai Inc.
Collaborators
—
Condition
Wild Type BRAF Stage IV Melanoma
Intervention
TMZ
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-07-28